The aim of this work package is to standardise the measurement of the non-specific marker for neurodegeneration and axonal damage: neurofilamentlight chain (NfL).
Task 2.1 will define what the target analyte is in a matrix (plasma or serum) and develop a reference measurement procedure by isotope dilution mass spectrometry (IDMS) for quantification of neurofilament in plasma or serum with a target uncertainty below 15 %.
Task 2.2 will explore the development of matrix-based prototype RMs and assess the commutability of those with available measurement techniques.
Task.2.3 will develop a routine, clinical LC-MS assay, allowing uptake of the RMP in clinical practice. Patient data will be correlated with analytical measurements with a potential to uncover new aspects of NfL that may aid patient stratification.

WP leader: Christopher Hopley, Emanuele Scollo, Eva Illes-Toth (LGC limited)